Top

Published in:

01-12-2023 | Urolithiasis | Research

An insight investigation to the antiurolithic activity of Trachyspermum ammi using the in vitro and in vivo experiments

Authors: Aslam Khan, Anwar H. Gilani

Published in: Urolithiasis | Issue 1/2023

Abstract

The crude extract of Trachyspermum ammi seeds (Ta.Cr) was studied for its antiurolithic activity using the in vivo and in vitro experiments. In the in vivo experiments, Ta.Cr treatment showed a diuretic activity at the dose of 30 and 100 mg/kg and exhibited curative effect in male hyperoxaluric Wistar rats, which received 0.75% ethylene glycol (EG) in drinking water given for 3 weeks, with 1% ammonium chloride (AC) for initial three days. In the in vitro experiments, Ta.Cr delayed the slopes of nucleation and inhibited the calcium oxalate (CaOx) crystal aggregation in a concentration-dependent manner like that of potassium citrate. Ta.Cr also inhibited DPPH free radicals like standard antioxidant drug butylated hydroxytoluene (BHT), and significantly reduced cell toxicity and LDH release in Madin–Darby canine kidney (MDCK) cells, exposed to oxalate (0.5 mM) and COM (66 µg/cm²) crystals. In isolated rabbit urinary bladder strips, Ta.Cr relaxed high K⁺ (80 mM) and CCh (1 µM)-induced contractions, showing antispasmodic activity. The findings of this study suggest that the antiurolithic activity of crude extract of Trachyspermum ammi seeds may be mediated by a number of mechanisms, including a diuretic, an inhibitor of CaOx crystal aggregation, an antioxidant, renal epithelial cell protection, and an antispasmodic, thus, showing the therapeutic potential in urolithiasis, for which there is no viable non-invasive option in modern medicine.

Lemann J Jr (1993) Composition of the diet and calcium kidney stones. N Engl J Med 328(12):880–882. https://doi.org/10.1056/NEJM199303253281212CrossRefPubMed

Evan AP (2010) Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 25(5):831–841. https://doi.org/10.1007/s00467-009-1116-yCrossRefPubMed

Khan SR (2013) Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol 189(3):803–811CrossRefPubMed

Khan SR (2012) Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res 40(2):95–112. https://doi.org/10.1007/s00240-011-0448-9CrossRefPubMedPubMedCentral

Tsujihata M, Momohara C, Yoshioka I, Tsujimura A, Nonomura N, Okuyama A (2008) Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol 180(5):2212–2217. https://doi.org/10.1016/j.juro.2008.07.024CrossRefPubMed

Gaspar S, Niculite C, Cucu D, Marcu I (2010) Effect of calcium oxalate on renal cells as revealed by real-time measurement of extracellular oxidative burst. Biosens Bioelectron 25(7):1729–1734. https://doi.org/10.1016/j.bios.2009.12.013CrossRefPubMed

Khan SR (2005) Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 33(5):349–357. https://doi.org/10.1007/s00240-005-0492-4CrossRefPubMed

Hollenberg D, Zakus D, Cook T, Xu XW (2008) Re-positioning the role of traditional, complementary and alternative medicine as essential health knowledge in global health: do they still have a role to play? World Health Popul 10(4):62–75PubMed

Gilani AH, Rahman AU (2005) Trends in ethnopharmocology. J Ethnopharmacol 100(1–2):43–49. https://doi.org/10.1016/j.jep.2005.06.001CrossRefPubMed

10.

Usmanghani K, Saeed A, Alam MT (1997) Indusyunic medicine. University of Karachi Press, Karachi

11.

Duke JA (2002) Handbook of medicinal herbs. CRC PressCrossRef

12.

Duke JA (1992) Handbook of phytochemical constituents of GRAS herbs and other economic plants. CRC Press Inc., Boca Raton, pp 292–293

13.

Srivastava KC (1988) Extract of a spice—omum (Trachyspermum ammi)-shows antiaggregatory effects and alters arachidonic acid metabolism in human platelets. Prostaglandins Leukot Essent Fatty Acids 33(1):1–6. https://doi.org/10.1016/0952-3278(88)90115-9CrossRefPubMed

14.

Boskabady MH, Shaikhi J (2000) Inhibitory effect of Carum copticum on histamine (H1) receptors of isolated guinea-pig tracheal chains. J Ethnopharmacol 69(3):217–227. https://doi.org/10.1016/s0378-8741(99)00116-6CrossRefPubMed

15.

Agrewala JN, Pant MC (1986) Effect of feeding Carum copticum seeds on serum lipids, high density lipoproteins & serum cholesterol binding reserve in the albino rabbits. Indian J Med Res 83:93–95PubMed

16.

Gilani AH, Jabeen Q, Ghayur MN, Janbaz KH, Akhtar MS (2005) Studies on the antihypertensive, antispasmodic, bronchodilator and hepatoprotective activities of the Carum copticum seed extract. J Ethnopharmacol 98(1–2):127–135. https://doi.org/10.1016/j.jep.2005.01.017CrossRefPubMed

17.

Zahin M, Ahmad I, Aqil F (2010) Antioxidant and antimutagenic activity of Carum copticum fruit extracts. Toxicol In Vitro 24(4):1243–1249. https://doi.org/10.1016/j.tiv.2010.02.004CrossRefPubMed

18.

Ahsan SK, Shah AH, Tanira MOM, Ahmad MS, Tariq M, Ageel AM (1990) Studies on some herbal drugs used against kidney stones in Saudi folk medicine. Fitoterapia 61(5):435–438

19.

Kaur T, Bijarnia RK, Singla SK, Tandon C (2009) In vivo efficacy of Trachyspermum ammi anticalcifying protein in urolithiatic rat model. J Ethnopharmacol 126(3):459–462. https://doi.org/10.1016/j.jep.2009.09.015CrossRefPubMed

20.

Williamson EM, Okpako DT, Evans FJ (1996) Selection, preparation, and pharmacological evaluation of plant material. John Wiley & Sons

21.

Khan A, Bashir S, Gilani AH (2012) An in vivo study on the diuretic activity of Holarrhena antidysenterica. Afr J Pharm Pharmacol 6(7):454–458

22.

Khan A, Gilani AH (2010) Pharmacological basis for the medicinal use of Origanum vulgare Linn. In: Urolithiasis [abstract]. Paper presented at the 16th world congress of basic and clinical pharmacology, Copenhagen, Denmark

23.

Khan A, Khan SR, Gilani AH (2012) Studies on the in vitro and in vivo antiurolithic activity of Holarrhena antidysenterica. Urol Res 40(6):671–681. https://doi.org/10.1007/s00240-012-0483-1CrossRefPubMedPubMedCentral

24.

Pizzolato P (1971) Mercurous nitrate as a histochemical reagent for calcium phosphate in bone and pathological calcification and for calcium oxalate. Histochem J 3(6):463–469. https://doi.org/10.1007/BF01014785CrossRefPubMed

25.

Hess B, Meinhardt U, Zipperle L, Giovanoli R, Jaeger P (1995) Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers. Urol Res 23(4):231–238. https://doi.org/10.1007/BF00393304CrossRefPubMed

26.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–275CrossRefPubMed

27.

Ebisuno S, Komura T, Yamagiwa K, Ohkawa T (1997) Urease-induced crystallizations of calcium phosphate and magnesium ammonium phosphate in synthetic urine and human urine. Urol Res 25(4):263–267. https://doi.org/10.1007/BF00942096CrossRefPubMed

28.

Guerra A, Meschi T, Allegri F, Schianchi T, Adorni G, Novarini A, Borghi L (2004) Calcium oxalate crystallization in untreated urine, centrifuged and filtered urine and ultrafiltered urine. Clin Chem Lab Med 42(1):45–50. https://doi.org/10.1515/CCLM.2004.009CrossRefPubMed

29.

Huang DJ, Chen HJ, Hou WC, Lin CD, Lin YH (2004) Active recombinant thioredoxin h protein with antioxidant activities from sweet potato (Ipomoea batatas [L.] Lam Tainong 57) storage roots. J Agric Food Chem 52(15):4720–4724. https://doi.org/10.1021/jf0498618CrossRefPubMed

30.

Borchert VE, Czyborra P, Fetscher C, Goepel M, Michel MC (2004) Extracts from Rhois aromatica and Solidaginis virgaurea inhibit rat and human bladder contraction. Naunyn Schmiedebergs Arch Pharmacol 369(3):281–286. https://doi.org/10.1007/s00210-004-0869-xCrossRefPubMed

31.

Ajith TA, Usha S, Nivitha V (2007) Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 375(1–2):82–86. https://doi.org/10.1016/j.cca.2006.06.011CrossRefPubMed

32.

Farre AJ, Colombo M, Fort M, Gutierrez B (1991) Differential effects of various Ca²⁺ antagonists. Gen Pharmacol 22(1):177–181. https://doi.org/10.1016/0306-3623(91)90331-yCrossRefPubMed

33.

Van Rossum JM (1963) Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 143:299–330PubMed

34.

Kalaiselvi P, Udayapriya KL, Selvam R (1999) Uric acid-binding proteins in calcium oxalate stone formers and their effect on calcium oxalate crystallization. BJU Int 83(9):919–923. https://doi.org/10.1046/j.1464-410x.1999.00084.xCrossRefPubMed

35.

Dasaeva LA, Shilov EM, Shatokhina SN (2003) Diuress for the treatment of early stages of urolithiasis. Klin Med (Mosk) 81(10):50–52PubMed

36.

Goldfarb DS, Coe FL (2005) The medical management of stone disease. In: Davison AM, Cameron JS, Ritz E, Grünfeld J, Winearls CG, Ponticelli C, van Ypersele C (eds) Oxford textbook of clinical nephrology. Oxford University Press, New York, pp 1199–1279

37.

Tsai CH, Chen YC, Chen LD, Pan TC, Ho CY, Lai MT, Tsai FJ, Chen WC (2008) A traditional Chinese herbal antilithic formula, Wulingsan, effectively prevents the renal deposition of calcium oxalate crystal in ethylene glycol-fed rats. Urol Res 36(1):17–24. https://doi.org/10.1007/s00240-007-0122-4CrossRefPubMed

38.

Vanachayangkul P, Chow N, Khan SR, Butterweck V (2011) Prevention of renal crystal deposition by an extract of Ammi visnaga L. and its constituents khellin and visnagin in hyperoxaluric rats. Urol Res 39(3):189–195. https://doi.org/10.1007/s00240-010-0333-yCrossRefPubMed

39.

Bashir S, Gilani AH (2011) Antiurolithic effect of berberine is mediated through multiple pathways. Eur J Pharmacol 651(1–3):168–175. https://doi.org/10.1016/j.ejphar.2010.10.076CrossRefPubMed

40.

Fan J, Glass MA, Chandhoke PS (1999) Impact of ammonium chloride administration on a rat ethylene glycol urolithiasis model. Scanning Microsc 13(2–3):299–306

41.

Park HK, Jeong BC, Sung MK, Park MY, Choi EY, Kim BS, Kim HH, Kim JI (2008) Reduction of oxidative stress in cultured renal tubular cells and preventive effects on renal stone formation by the bioflavonoid quercetin. J Urol 179(4):1620–1626. https://doi.org/10.1016/j.juro.2007.11.039CrossRefPubMed

42.

Thamilselvan S, Khan SR, Menon M (2003) Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 31(1):3–9. https://doi.org/10.1007/s00240-002-0286-xCrossRefPubMed

43.

Wiessner JH, Hasegawa AT, Hung LY, Mandel GS, Mandel NS (2001) Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells. Kidney Int 59(2):637–644. https://doi.org/10.1046/j.1523-1755.2001.059002637.xCrossRefPubMed

44.

Tiselius HG (2003) Epidemiology and medical management of stone disease. BJU Int 91(8):758–767. https://doi.org/10.1046/j.1464-410x.2003.04208.xCrossRefPubMed

45.

Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinman JG (1998) Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53(4):952–957. https://doi.org/10.1111/j.1523-1755.1998.00839.xCrossRefPubMed

46.

Wesson JA, Ward MD (2006) Role of crystal surface adhesion in kidney stone disease. Curr Opin Nephrol Hypertens 15(4):386–393. https://doi.org/10.1097/01.mnh.0000232879.50716.6fCrossRefPubMed

47.

Guerra A, Meschi T, Allegri F, Prati B, Nouvenne A, Fiaccadori E, Borghi L (2006) Concentrated urine and diluted urine: the effects of citrate and magnesium on the crystallization of calcium oxalate induced in vitro by an oxalate load. Urol Res 34(6):359–364. https://doi.org/10.1007/s00240-006-0067-zCrossRefPubMed

48.

Wang AY (2009) Vascular and other tissue calcification in peritoneal dialysis patients. Perit Dial Int 29(Suppl 2):S9–S14CrossRefPubMed

49.

Khan SR (1997) Animal models of kidney stone formation: an analysis. World J Urol 15(4):236–243. https://doi.org/10.1007/BF01367661CrossRefPubMed

50.

Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A (2004) Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int 72(Suppl 1):6–10. https://doi.org/10.1159/000076583CrossRefPubMed

51.

Carvalho M, Vieira MA (2004) Changes in calcium oxalate crystal morphology as a function of supersaturation. Int Braz J Urol 30(3):205–208. https://doi.org/10.1590/s1677-55382004000300005CrossRefPubMed

52.

Kato Y, Yamaguchi S, Yachiku S, Nakazono S, Hori J, Wada N, Hou K (2004) Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology 63(1):7–11. https://doi.org/10.1016/j.urology.2003.09.057CrossRefPubMed

53.

Aihara K, Byer KJ, Khan SR (2003) Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 64(4):1283–1291. https://doi.org/10.1046/j.1523-1755.2003.00226.xCrossRefPubMed

54.

Escobar C, Byer KJ, Khaskheli H, Khan SR (2008) Apatite induced renal epithelial injury: insight into the pathogenesis of kidney stones. J Urol 180(1):379–387. https://doi.org/10.1016/j.juro.2008.02.041CrossRefPubMedPubMedCentral

55.

Byer K, Khan SR (2005) Citrate provides protection against oxalate and calcium oxalate crystal induced oxidative damage to renal epithelium. J Urol 173(2):640–646. https://doi.org/10.1097/01.ju.0000143190.49888.c7CrossRefPubMed

56.

Santhosh Kumar M, Selvam R (2003) Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. J Nutr Biochem 14(6):306–313. https://doi.org/10.1016/s0955-2863(03)00033-0CrossRefPubMed

57.

Babich H (1982) Butylated hydroxytoluene (BHT): a review. Environ Res 29(1):1–29. https://doi.org/10.1016/0013-9351(82)90002-0CrossRefPubMed

58.

Ohgaki K, Horiuchi K, Hikima N, Kondo Y (2010) Facilitation of expulsion of ureteral stones by addition of alpha1-blockers to conservative therapy. Scand J Urol Nephrol 44(6):420–424. https://doi.org/10.3109/00365599.2010.497769CrossRefPubMed

59.

Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U (2009) Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol 56(3):455–471. https://doi.org/10.1016/j.eururo.2009.06.012CrossRefPubMed

60.

Bolton TB (1979) Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev 59(3):606–718. https://doi.org/10.1152/physrev.1979.59.3.606CrossRefPubMed

61.

Godfraind T, Miller R, Wibo M (1986) Calcium antagonism and calcium entry blockade. Pharmacol Rev 38(4):321–416PubMed

62.

Brown JH, Taylor P (2006) Muscarinic receptor agonists and antagonists. Goodman and Gilman’s manual of pharmacology and therapeutics, 11th edn. McGraw-Hill Professional, New York, pp 183–200

63.

Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol 17(1):149–166. https://doi.org/10.1146/annurev.pa.17.040177.001053CrossRefPubMed

Title: An insight investigation to the antiurolithic activity of Trachyspermum ammi using the in vitro and in vivo experiments
Authors: Aslam Khan
Anwar H. Gilani
Publication date: 01-12-2023
Publisher: Springer Berlin Heidelberg
Keyword: Urolithiasis
Published in: Urolithiasis / Issue 1/2023
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-023-01415-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

An insight investigation to the antiurolithic activity of Trachyspermum ammi using the in vitro and in vivo experiments

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Asymptomatic bacteriuria in candidates for active treatment of renal stones: results from an international multicentric study on more than 2600 patients

Value of detected hydronephrosis and hydroureter on ultrasound for detecting a ureteral stone: a retrospective study

A randomized, double-blind, placebo-controlled clinical trial of the use of hydroxycitric acid adjuvant to shock wave lithotripsy therapy in patients with calcium stones. Stone fragmentation results

Effect of outflow resistance on intrarenal pressure at different irrigation rates during ureteroscopy: in vivo evaluation

Long-term follow-up on dusting versus basketing during ureteroscopy: a prospective multicenter trial from the EDGE Research Consortium

Can additional variables be used to predict stone-free rates following retrograde intrarenal surgery? Anticoagulants and parenchyma thickness: a detailed examination